Medivir is a pharmaceutical company dedicated to the development of innovative cancer therapies, particularly targeting cancers with high unmet medical needs. The company emphasizes its commitment to providing effective treatment options for patients who have limited alternatives. Medivir's approach is characterized by a balanced project portfolio and a collaborative culture, which enables them to efficiently advance their research and development efforts. Their scientific expertise and extensive industry experience contribute to a high success rate in bringing transformative drugs from discovery through clinical development to market.

Among Medivir's notable projects are Fostroxacitabine bralpamide, an oral nucleotide DNA polymerase inhibitor, and Birinapant/IGM-9427, an intravenous SMAC mimetic. These projects reflect the company's focus on leveraging advanced scientific knowledge to create impactful cancer treatments. Additionally, Medivir values partnerships as a crucial aspect of its business strategy, having successfully collaborated with various partners to transition products from research to global launch. This collaborative approach enhances their ability to address significant medical needs in oncology.

Sweden

Medivir is a drug discovery and development company focusing on transformative cancer drugs. Their research and development are based on their extensive knowledge of protease inhibition and nucleoside/nucleotide science. The company is headquartered in Stockholm, Sweden.

Medivir

Company Details